Byetta
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
AstraZeneca ‘rejects Pfizer bid’
April 22, 2014Research and Development, Sales and Marketing AstraZeneca, Byetta, Onglyza, Pfizer, Soriot, merger
AstraZeneca has rebuffed a £60 billion bid from Pfizer, according to media reports. Both companies have declined to comment on …
AstraZeneca ‘simplifies decision-making’
February 4, 2014Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes
AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …
Amylin withheld safety data, says FDA
June 27, 2012Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, FDA, lilly
The US medicines regulator says Amylin held back data relating to the safety of its diabetes drug Bydureon. The allegation …
Amylin to pay up to $1.6 billion to sever ties with Lilly
November 8, 2011Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, R&D, lilly
Amylin will pay up to $1.6 billion to end its diabetes pact with Lilly after a difficult year for the …
Novo Nordisk’s Victoza launched in China
October 10, 2011Sales and Marketing Byetta, China, Victoza, diabetes
Novo Nordisk’s Victoza is now available in China, one of the fastest growing diabetes markets in the world. Victoza (liraglutide …
Fresh scrutiny for new diabetes drugs
September 15, 2011Sales and Marketing Byetta, GLP-1, Januvia, Merck, Novo Nordisk, Victoza, diabetes
Merck’s Januvia and Lilly’s Byetta face renewed safety questions this week as the European Association for the Study of Diabetes …
Diabetes drugs show promise in Alzheimer’s
January 17, 2011Research and Development Alzheimer's, Alzheimer’s, Byetta, Novo Nordisk, Victoza, diabetes, exenatide, lilly, liraglutide
Research suggests that new diabetes drugs enhance cell growth in the brain, and could help treat Alzheimer’s disease. Researchers at …
FDA questions delay long-acting Byetta
March 17, 2010Manufacturing and Production Bydureon, Byetta, Syncria, Victoza
A once-weekly formulation of Eli Lilly and Amylin Pharmaceuticals’ blockbuster diabetes medication Byetta has hit a manufacturing hurdle en route …
New diabetes drug launched in UK
March 14, 2007Sales and Marketing Byetta, diabetes
A new diabetes medicine, which mimics the body's natural processes for controlling blood sugar, has been launched in the UK.The …
New diabetes drug Byetta set for European approval
September 22, 2006Sales and Marketing Byetta, diabetes
Lilly and Amylin's new diabetes treatment Byetta is set for European approval following recommendation from medicines regulator the EMEA.Byetta (exenatide) …
